Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue

Bristol Myers Squibb demonstrates steadier year-over-year revenue growth with consistent upward trends, while Pfizer shows higher absolute revenue but experienced recent fluctuations and contraction periods. BMY's revenue is projected to edge up 3% to $49.9 billion with net income rising over 40%, while PFE's revenue is expected to slump slightly to $62.2 billion despite net income gains. Based on revenue trends alone, Bristol Myers Squibb appears to be on a better trajectory, though both companies show positive comparable quarter-over-quarter growth.

10/22/2026, 5:25 PM • The Motley Fool

Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight

The global oral drugs market is experiencing steady growth driven by increasing chronic disease prevalence and patient preference for convenient treatment options. The market is projected to grow from USD 1 trillion in 2025 to USD 1.6 trillion by 2034 at a ~6% CAGR. North America leads with 36% market share, while Asia-Pacific is expected to register the fastest growth. Key drivers include advancements in drug delivery technologies, expansion of oral therapies across oncology and other therapeutic areas, and rising pharmaceutical R&D investments.

10/21/2026, 1:00 PM • GlobeNewswire

Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice

Moderna is transitioning from a COVID-19 vaccine company to an oncology-focused biotech firm. The company announced positive phase 3 results for its personalized cancer vaccine (intismeran autogene) paired with Merck's Keytruda for melanoma treatment. With the global oncology market projected to grow from $253 billion to over $700 billion by 2034, Moderna's stock has surged over 600% this year, though it now trades 61% above Wall Street's average price target of $123.

10/21/2026, 4:02 AM • The Motley Fool

Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?

Pfizer stock has gained 18% this year amid a potential rotation from tech to healthcare stocks. The company offers an attractive 5.8% dividend yield and trades at a forward P/E multiple of around 10, suggesting significant undervaluation despite a high trailing P/E of 37 due to restructuring charges. Analysts believe the stock has substantial upside potential as the market recognizes its value.

10/19/2026, 5:27 PM • The Motley Fool

Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight

The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.

10/19/2026, 1:00 PM • GlobeNewswire

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

BioNTech faces mounting clinical setbacks in its cancer vaccine pipeline, including a halted Phase 2 trial for autogene cevumeran and BNT113's failure to meet a primary endpoint in head and neck cancer trials. With COVID-19 vaccine revenues declining sharply (down 60% YoY) and the company unprofitable, investors must weigh the deep pipeline potential against significant uncertainty. The stock is recommended only for risk-tolerant investors.

10/18/2026, 2:32 PM • The Motley Fool

Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Year

The article examines five high-yield dividend stocks with yields ranging from 5.88% to 16.72%. Featured stocks include Altria Group (5.93% yield, 57-year dividend streak), AGNC Investment (16.72% yield but at risk from rising rates), Energy Transfer (6.57% yield, 19 consecutive quarters of increases), Pfizer (6.06% yield, 352 consecutive quarterly dividends), and Realty Income (5.88% yield, 116 consecutive quarters of increases). While these stocks offer steady income, investors should be aware of sector-specific risks including interest rate sensitivity and commercial real estate headwinds.

10/18/2026, 10:30 AM • The Motley Fool

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

BioNTech has 16.6 billion euros in cash and is advancing 14 pivotal oncology trials, positioning itself to transition from a COVID-19 vaccine maker to a major cancer treatment company. With a diversified pipeline including promising candidates like pumitamig and a $1 billion share repurchase program, the company has financial flexibility to fund development. However, risks include trial failures, declining COVID-19 revenue, and regulatory delays.

10/17/2026, 12:23 PM • The Motley Fool

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Bristol-Myers Squibb and Johnson & Johnson as healthcare investment options. BMY trades at a cheaper valuation (9.3x forward P/E vs JNJ's 21x) with a higher dividend yield of 4.16%, but faces patent cliffs and pricing pressures. JNJ offers greater revenue scale ($94.2B vs $48.2B), diversified business segments, and a 64-year dividend growth streak, making it the recommended choice for 2026 despite its premium valuation.

10/16/2026, 8:50 PM • The Motley Fool

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

AbbVie, a Dividend King with 53 consecutive years of dividend increases, would require 723 shares (approximately $206,358) to generate $5,000 in annual dividends at its current price. Despite a modest 2.4% forward yield, the pharmaceutical giant's strong portfolio of blockbuster drugs, low P/E ratio of 16, and 93% stock rally over three years make it an attractive long-term income investment, even compared to higher-yielding alternatives like Pfizer.

10/16/2026, 5:28 PM • The Motley Fool

Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?

Pfizer declared its 352nd consecutive quarterly dividend with a 5.9% yield, significantly higher than the S&P 500 average of 1%. While the company faces patent cliffs on major drugs like Eliquis and Xeljanz this year, it maintains a robust pipeline focused on cancer treatments and generated $11 billion in free cash flow over the past four quarters, exceeding dividend payments. Management remains committed to maintaining and growing the dividend, though investors must have confidence in the company's ability to replace expiring patents with new pipeline drugs.

10/16/2026, 2:53 PM • The Motley Fool

Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

Johnson & Johnson raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to exceed $100 billion in annual revenue for the first time. Strong pharmaceutical demand, particularly in cancer treatments, drove performance. However, the medical device segment faced headwinds with only 2.5% growth due to Middle East disruptions and China's bulk-buying program. Management plans to restore momentum through new product launches and is leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027.

10/16/2026, 1:54 PM • The Motley Fool

6 Blue Chip Stocks Trading Well Below Their Highs

Six major blue-chip stocks—Nike, Goldman Sachs, Intel, Disney, Pfizer, and Home Depot—are trading at least 20% below their all-time highs despite a strong bull market. The article analyzes each stock to determine whether they represent bargains or value traps, considering factors like valuation metrics, competitive pressures, and market sentiment.

10/16/2026, 5:30 AM • The Motley Fool

2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends

Verizon Communications and Pfizer are highlighted as attractive high-yield dividend stocks for income investors. Verizon offers a 6.5% forward dividend yield backed by strong subscriber growth and improved customer retention, while Pfizer provides a 6.1% yield with a 352-consecutive-quarter dividend history and growth potential from its oncology pipeline and 96 research programs.

10/15/2026, 4:23 PM • The Motley Fool

Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight

Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.

10/15/2026, 1:00 PM • GlobeNewswire